Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Mc Cain

Surgical Oncology Hackensack, NJ Medical Doctor

NPI 1295801157 CMS profile 1141244

20 Prospect Ave, Suite 603, Hackensack, NJ 07601

Open in the dashboard

General payments

$6,669

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donald Mc Cain of Hackensack, NJ is reported in the CMS Open Payments database as having received $6,669 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107 4
2024 General $2,374 8
2023 General $4,007 11
2022 General $145 2
2020 General $25 1
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Mc Cain
  • Surgical Oncology median
  • Middle half of Surgical Oncology
  • National median

In program year 2025, general payments to Donald Mc Cain were reported at $107. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.

Show as a table
Year Donald Mc Cain Surgical Oncology median Middle half National median
2019 $12 $236 $86–$1,064 $163
2020 $25 $130 $47–$648 $114
2021 $0 $160 $53–$943 $132
2022 $145 $199 $76–$782 $149
2023 $4,007 $246 $95–$854 $160
2024 $2,374 $271 $106–$1,123 $164
2025 $107 $288 $118–$1,346 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kerecis Limited $4,012 10 payments
  2. Intuitive Surgical, Inc. $2,345 11 payments
  3. Sanara MedTech Inc. $115 1 payment
  4. Medtronic, Inc. $115 1 payment
  5. Davol Inc. $28 1 payment
  6. Ethicon US, LLC $25 1 payment
  7. Integra LifeSciences Corporation $17 1 payment
  8. Janssen Biotech, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,000 1 payment
  2. Travel and Lodging $1,899 7 payments
  3. Food and Beverage $1,753 17 payments
  4. Education $1,000 1 payment
  5. Gift $16 1 payment
Products named General payments · program years 2019–2025
  1. Kerecis Omega3 SurgiClose Wound Care $3,905 6 payments
  2. Kerecis Omega3 GraftGuide $3,710 5 payments
  3. Kerecis Omega3 SurgiClose Wound Care $3,305 3 payments
  4. Kerecis Omega3 Marigen Wound Care $3,305 3 payments
  5. Kerecis Omega3 SurgiClose Wound Care $3,305 3 payments
  6. Da Vinci Surgical System $1,345 10 payments
  7. DAVINCI XI $1,000 1 payment
  8. Kerecis Omega3 Marigen Wound Care $600 3 payments
  9. Kerecis Omega3 Marigen Wound Care $405 2 payments
  10. Kerecis Omega3 Marigen Wound Care $405 2 payments
  11. Other $1,524 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

363

Median for Surgical Oncology: 44

Drug cost

$2,269

Median for Surgical Oncology: $327

Branded share of claims

14.6%

Median for Surgical Oncology: 14.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 20 $1,381
Azithromycin Generic 123 $417
Tramadol Hcl Generic 115 $180
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 33 $134
Oxycodone Hcl Generic 34 $114
Ciprofloxacin Hcl Generic 25 $31
Metronidazole Generic 13 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 682 Part D prescribers listed as Surgical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$304,603

Medicare's payments for the services billed

Medicare patients

224

Average age 75

Services billed

719

100 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 41%
Cancer 37%
Diabetes 35%
COPD 23%
Chronic kidney disease 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgical Oncology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record